EGFRAP encodes a new negative regulator of the EGFR acting in both normal and oncogenic EGFR/Ras-driven tissue morphogenesis.
Activation of Ras signaling occurs in ~30% of human cancers. However, activated Ras alone is insufficient to produce malignancy. Thus, it is imperative to identify those genes cooperating with activated Ras in driving tumoral growth. In this work, we have identified a novel EGFR inhibitor, which we...
Guardado en:
Autores principales: | Jennifer Soler Beatty, Cristina Molnar, Carlos M Luque, Jose F de Celis, María D Martín-Bermudo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4e3c5c6576e54e079590b3e69a6c23d4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
EGFR/ARF6 regulation of Hh signalling stimulates oncogenic Ras tumour overgrowth
por: Chiswili Chabu, et al.
Publicado: (2017) -
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Beth O. Van Emburgh, et al.
Publicado: (2016) -
Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen M, et al.
Publicado: (2018) -
Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
por: Shang-Gin Wu, et al.
Publicado: (2011) -
Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patients
por: Masykura N, et al.
Publicado: (2019)